Handa Pharmaceuticals, LLC | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Handa Pharmaceuticals, LLC

Sort by

Viewing results 1‒25 of 430

Illumina Inc
Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture
World’s biggest gene sequencing company rejects EU’s fast- track application
May 27, 2023
Centerview Partners LLC
US boutique adviser Centerview names first co-presidents
...Tokat, 46, joined Centerview in 2009 with a group from Merrill Lynch that specialised in pharmaceutical and biotech companies....
April 21, 2023
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
The crisis in European equities
Flight risk? London listings are the most vulnerable to New York’s allure
...Activist investors want to split the group’s pharmaceuticals business from its crop science unit to optimise its valuation....
May 26, 2023
Credit Suisse Group AG
UBS to enter talks with Michael Klein to terminate First Boston deal
...Hamers also wants to retain bankers specialising in pharmaceuticals, media and telecoms, which UBS believes will provide a pipeline of wealthy customers for its private bank....
March 21, 2023
Mergers & Acquisitions
EU wrong to block Illumina’s $8bn takeover of Grail, says court adviser
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
March 21, 2024
Illumina Inc
EU regulators to order Illumina to sell $8bn cancer treatment group
Rare step comes after Brussels fined US biotech for buying Grail without approval
October 9, 2023
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
LexPharmaceuticals sector
23andMe: DNA testing kit company needs drug discovery Premium content
Money for research will be required but salvation may come from a partnership with GSK
August 22, 2023
Illumina Inc
Glass Lewis backs Carl Icahn’s push to oust Illumina’s chief and chair
Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail
May 10, 2023
Illumina Inc
Illumina faces record fine over purchase of Grail without EU approval
World’s biggest gene sequencing group closed deal with cancer screening start-up despite ongoing investigation
July 4, 2023
LexMergers & Acquisitions
Pharma: M&A strategy gets dose of bitter medicine Premium content
Antitrust challenge may force big pharma groups to rethink ‘pure play’ business models
June 12, 2023
Biotech
Grail sued by three female ex-employees over ‘toxic work culture’
Illumina-owned cancer testing group allegedly failed to deal with accusations of inappropriate behaviour and racism
July 13, 2023
Illumina Inc
Illumina hit with record €432mn fine for ignoring EU concerns over Grail deal
US gene sequencing company proceeded with acquisition of cancer test developer even as regulators were probing deal
July 12, 2023
The Art of FashionThe Art of Fashion: the Literary issue
Novelist Ottessa Moshfegh finds joy in simple clothes
...In her hit 2018 novel My Year of Rest and Relaxation, Moshfegh’s narrator — a rich, depressed young woman with a face like Amber Valletta’s and a plan to ingest as many pharmaceuticals as it takes to sleep...
August 22, 2023
Health sector
More than 400 Grail patients incorrectly told they may have cancer
Error prompts life assurance customers to pause or review relationship with early detection biotech
June 2, 2023
Mergers & Acquisitions
Buffett’s favoured advisory firm takes stake in Italian machinery maker IMA
...Founded in 1961, IMA designs and manufactures machines for the processing and packaging of pharmaceuticals, cosmetics and food, among other things....
July 31, 2023
FT Live
Due Diligence Live
Where leaders in investment and finance meet
Tuesday, 8 OctoberLondon, UK
Illumina Inc
Carl Icahn says Illumina directors demanded extra insurance for Grail deal
Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer
March 24, 2023
Illumina Inc
Carl Icahn takes aim at genome sequencer Illumina over Grail deal
Company’s shares jump after activist investor launches proxy battle
March 13, 2023
Mergers & Acquisitions
US antitrust regulator orders Illumina to unwind $8bn Grail deal
FTC warns acquisition would hurt competition in the market for early detection cancer tests
April 3, 2023
The Big Read
Transformers: the Google scientists who pioneered an AI revolution
...The company has already delivered AI-designed molecules for infectious disease vaccines to a large pharmaceutical company....
July 23, 2023
Illumina Inc
Illumina battle with regulators threatens cancer breakthrough, warn Grail alumni
Founding directors say political wrangling causing delays to potentially life-saving blood test
April 4, 2023
THG PLC
THG receives takeover bid from Apollo
...In the past week, credit card processor, London-listed Network International Holdings and Dechra Pharmaceuticals have announced that they are fielding interest from buyout firms including CVC Capital Partners...
April 17, 2023
Banks in turmoil
What the takeover of Credit Suisse means for UBS
...UBS managers believe advantages come with retaining bankers who specialise in growth areas such as pharmaceuticals, technology, media and telecoms, because the owners of the businesses could be persuaded...
March 22, 2023
FT Swamp Notes
The intention of algorithms Premium content
...Every business that says they are “special” (like banking in the run-up to 2008, or pharmaceutical firms today) tends to be trying to pull one over on regulators and the public....
February 10, 2023
Special ReportAsia-Pacific Innovative Lawyers
Practice of law: best practice in legal work
...Paul Hastings O: 6; L: 7; I: 7; Total: 20The firm advised South Korean pharmaceutical company SD Biosensor and South Korean private equity fund SJL Partners on the acquisition of US-listed pharmaceutical...
May 5, 2023
US equities
Cancer drug company accuses US market makers of stock spoofing
Northwest Biotherapeutics claims Citadel Securities, Virtu and others drove down its share price
December 1, 2022

Previous pagePage 1 of 18Next page